Scout Bio is a technology company.
Scout Bio has raised $53.0M across 2 funding rounds.
Key people at Scout Bio.
Scout Bio has raised $53.0M in total across 2 funding rounds.
Key people at Scout Bio.
Scout Bio is a biotechnology company developing one-time AAV gene therapies and monoclonal antibodies to treat chronic conditions in pets, such as anemia from chronic kidney disease (CKD), diabetes, and arthritis pain.[1][2][3] It serves pet owners and veterinarians by providing single-injection treatments that induce long-term expression of therapeutic proteins via adeno-associated viral (AAV) vectors, primarily through intramuscular delivery for enhanced durability and convenience.[1][2] The company addresses the limitations of frequent injections for chronic pet diseases, with a pipeline showing early clinical successes like pilot studies in feline CKD-anemia and diabetes.[3][5] Headquartered in Philadelphia, Scout Bio originated as a University of Pennsylvania spin-out and was acquired by Ceva Santé Animale in January 2024, accelerating its biotherapeutics for companion animals.[1][4][6]
Scout Bio emerged as a spin-out from the University of Pennsylvania's Gene Therapy Program (GTP), led by pioneering gene therapy expert Dr. James M. Wilson, director of GTP and the Rose H. Weiss Professor.[3][4] Founded around 2020-2021, it leveraged GTP's expertise in AAV vectors to target veterinary applications, marking industry firsts like the first gene therapy in clinical development for feline CKD-associated anemia and a novel GLP-1 analog for feline diabetes.[3][5] Early traction included a $20 million financing round and successful pilot studies, such as the completion of a feline CKD-anemia trial with SB-001 in 2021, followed by a $33 million Series B2 in 2023 to advance diabetes, pain, and anemia programs.[5] Named Best New Start-Up for 2021 by IHS Markit, Scout Bio expanded its GTP collaboration before Ceva Santé Animale's acquisition in January 2024, which preserved ties to Penn while boosting global development.[3][4][5][6]
Scout Bio rides the gene therapy wave in veterinary medicine, adapting human AAV successes to pets amid rising pet humanization and demand for chronic disease solutions—pets now represent a $150+ billion market with unmet needs in conditions like CKD, diabetes, and pain.[1][2][3] Timing aligns with maturing AAV platforms, proven safe in humans, now proving durable in animals via intramuscular delivery, potentially disrupting monthly injectables.[2][3] Market forces favor it: pet ownership surges post-pandemic, regulatory paths for vet biologics are opening, and Ceva's #5 global animal health position provides distribution muscle.[4][6] It influences the ecosystem by validating AAV for non-monogenic vet diseases, inspiring cross-species applications and fostering biotech-vet med convergence.[2][3][4]
With Ceva's backing, Scout Bio is poised to launch its first therapies, targeting feline CKD-anemia and diabetes by advancing multi-center trials like its cat arthritis pain study.[4][5] Trends like AI-optimized vectors, expanded monoclonal pipelines, and global vet biotech growth will propel it, potentially evolving AAV into a standard for pet chronic care.[2][4] Its influence may expand via new Penn collaborations, influencing human-animal translational medicine and cementing one-time dosing as pet med's future—transforming Scout Bio from nimble startup to biotherapeutics leader.[1][3][4]
Scout Bio has raised $53.0M in total across 2 funding rounds.
Scout Bio's investors include Abingworth, Bain Capital Life Sciences, Digitalis Ventures, MRL Ventures Fund, RiverVest, SV Health Investors.
Scout Bio has raised $53.0M across 2 funding rounds. Most recently, it raised $33.0M Series B in October 2021.
| Date | Round | Lead Investors | Other Investors |
|---|---|---|---|
| Oct 1, 2021 | $33.0M Series B | Abingworth, Bain Capital Life Sciences, Digitalis Ventures, MRL Ventures Fund, RiverVest, SV Health Investors | |
| Mar 1, 2019 | $20.0M Series B | Abingworth, Bain Capital Life Sciences, Digitalis Ventures, MRL Ventures Fund, RiverVest, SV Health Investors |
